Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Rhea-AI Summary
Indivior (Nasdaq: INDV) will report first quarter 2026 financial results on Thursday, April 30, 2026 at 7:00 a.m. U.S. EDT. A live webcast presentation with CEO Joe Ciaffoni and other leaders will follow at 8:00 a.m. U.S. EDT.
Investors can access the live webcast and materials on the company’s Investors webpage; a replay will be available after the event.
Positive
- None.
Negative
- None.
News Market Reaction – INDV
In the Apr 9 session, INDV gained 1.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Earnings date set | Neutral | +0.6% | Scheduled Q4 and full-year 2025 results webcast with CEO-led presentation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news triggered only modest share-price movement, suggesting limited typical impact from timing/webcast announcements alone.
Recent news flow combined operational and financing milestones. In March 2026, INDV issued $500,000,000 of 0.625% Convertible Senior Notes due 2031 and detailed use of proceeds in related offerings. A DEF 14A filing highlighted 2025 growth: net revenue of $1.24 billion, SUBLOCADE net revenue of $856 million, GAAP net income of $210 million, and adjusted EBITDA of $428 million. Against this backdrop, the prior earnings-date announcement on January 28, 2026 produced a modest 0.55% move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.
Access to the Live Webcast Presentation:
The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.
Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp
Participants may access the presentation telephonically by registering with the following link:
https://register-conf.media-server.com/register/BIea9b995134de41e68f49a057c2a6cb66
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
A replay of the presentation will be available at www.indivior.com.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
For Further Information
Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com
Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com
